Table II.
Hybrid Revascularization Patient Characteristics by Relative Timing of CABG and PCI.
| Hybrid Revascularizations | p-value | ||
|---|---|---|---|
| PCI Then CABG N=774 |
CABG Then PCI N=324 |
||
| Demographics | |||
| Age | 64.0 (56.0, 71.0) | 67.0 (61.0, 74.0) | <0.001 |
| Male Gender | 71.1% | 68.8% | 0.46 |
| White Race | 84.8% | 85.8% | 0.66 |
| Clinical Characteristics | |||
| ACS Admission | 90.3% | 63.9% | <0.001 |
| Previous MI | 24.7% | 29.6% | 0.09 |
| Previous CHF | 9.2% | 19.8% | <0.001 |
| Diabetes | 37.5% | 50.6% | <0.001 |
| Cerebrovascular Disease | 10.7% | 21.0% | <0.001 |
| Peripheral Vascular Disease | 9.7% | 19.1% | <0.001 |
| Chronic Lung Disease | 15.0% | 17.9% | 0.23 |
| Hypertension | 82.3% | 87.7% | 0.03 |
| Dyslipidemia | 75.7% | 83.3% | 0.006 |
| Previous PCI | 24.9% | 27.5% | 0.38 |
| Currently on Dialysis | 1.9% | 8.3% | <0.001 |
| Procedure Characteristics | |||
| Multivessel PCI | 11.2% | 35.8% | <0.001 |
| Lesion Treated with PCI | |||
| RCA territory | 49.4% | 41.0% |
<0.001 |
| Circumflex territory | 31.5% | 40.1% | |
| LAD territory | 17.4% | 6.2% | |
| Drug Eluting Stent Use | 60.1% | 85.5% | <0.001 |
| Discharge Medications | |||
| Aspirin | 97.1% | 96.8% | 0.44 |
| P2Y12 Inhibitor | 79.4% | 96.8% | <0.001 |
| Clopidogrel | 75.6% | 88.8% | <0.01 |
| Prasugrel | 2.6% | 3.2% | 0.63 |
| Ticagrelor | 1.2% | 5.1% | <0.001 |
| Statin | 93.9% | 94.8% | 0.17 |
| Beta Blocker | 94.0% | 94.6% | 0.30 |
| ACE Inhibitor or Angiotensin Receptor Blocker | 47.7% | 40.0% | 0.04 |